Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

NCT01301599 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

308

Enrollment

OTHER

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: combination therapy
DRUG: alpha blocker monotherapy
DRUG: 5 alpha reductase inhibitor monotherapy

Sponsor

Samsung Medical Center